Soluble ST2 in Patients With Heart Failure"

Assiut University

Status: Not yet enrolling

Conditions: Heart Failure Patients

Treatments: Diagnostic Test: ST2

Study type: Observational

Funder types: Other

Identifiers

NCT06426368

ST2 in H.F patients

Details and patient eligibility

About

1. The aim of this study was to explore the relationship between peripheral circulating serum soluble suppression of tumorigenicity-2 (sST2) levels and inflammatory biomarkers in patients with heart failure
2. Additive role of sST2 to NPs in of heart failure patients

Full description

Heart failure (HF), a complex and heterogeneous medical syndrome characterized by structural and functional cardiac abnormalities and hemodynamic disruptions, represents the end-stage manifestation of numerous cardiovascular disorders . HF is categorized into three groups based on the measurement of the left ventricular (LV) ejection fraction (LVEF) according to the European Society of Cardiology (ESC) Guidelines issued in 2021: HF with reduced ejection fraction (HFrEF, LVEF ≤ 40%), HF with mildly reduced ejection fraction (HFmrEF, LVEF 41-49%), and HF with preserved ejection fraction (HFpEF, LVEF ≥ 50%) .

Quantifying concentrations of circulating biomarkers plays a major role in most cardiovascular (CV) diseases, including (HF) .

An ideal biomarker in HF should be measured non-invasively and at low cost, highly sensitive to allow for the early detection of the disease .

N-terminal pro-B-type natriuretic peptide (NT-proBNP) released by cardiac muscle tissue in response to abnormal volume load is an established indicator for the diagnosis and prognosis of HF .

However, there are important limitations to natriuretic peptide (NP) testing in HF .

Soluble suppression of tumorigenicity-2 (sST2) is the circulating form of the interleukin-33 membrane receptor released in response to inflammation, fibrosis in various organs, and myocardium stress .

Soluble (s)ST2 has been proposed as a useful biomarker for heart failure (HF) patient management. Myocardial damage or mechanical stress stimulate sST2 release. ST2 competes with a membrane bound receptor (ST2 ligand, or ST2L) for interleukin-33 (IL-33) binding, inhibiting the effects induced by the ST2L/IL-33 interaction so that excessive sST2 may contribute to myocardial fibrosis and ventricular remodelling.

So biomarkers such as NT-proBNP and sST2 could potentially be used as surrogates for clinical outcomes in patients with HF and may be useful in monitoring disease progression and assessing the response to therapy .

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients 18-80 years.
• Both sexes will be included.
• including signs and symptoms of HF (e.g., elevated jugular venous pressure and altered apical beat position), altered LVEF (< 40%; 40%-49%; ≥ 50%)

Exclusion criteria

• Patients <18 years
• Patients with documented evidence of cardiogenic shock .
• Patients with Acute coronary syndrome within 30 days.
• chronic kidney disease patients with glomerular filtration rate < 30
• Patients with interstitial pulmonary fibrosis .

Trial design

100 participants in 3 patient groups

Group I

Description:

HF with reduced ejection fraction (HFrEF, LVEF ≤ 40%)

Treatment:

Diagnostic Test: ST2

Group II

Description:

HF with mildly reduced ejection fraction (HFmrEF, LVEF 41-49%)

Treatment:

Diagnostic Test: ST2

Group III

Description:

HF with preserved ejection fraction (HFpEF, LVEF ≥ 50%)

Treatment:

Diagnostic Test: ST2